30 results
8-K
EX-99.3
CLNN
Clene Inc
16 Apr 24
Regulation FD Disclosure
4:06pm
that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene
8-K
EX-99.1
CLNN
Clene Inc
13 Mar 24
Clene Reports Full Year 2023 Financial Results
8:02am
-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD
8-K
EX-99.2
kyk m4w5xm2zkte5or
29 Feb 24
Regulation FD Disclosure
8:05am
8-K
EX-99.2
zspi59
22 Feb 24
Regulation FD Disclosure
8:04am
8-K
EX-99.2
eaob5x8
8 Jan 24
Regulation FD Disclosure
7:07am
8-K
EX-99.2
tbd2x9vss5
21 Dec 23
Regulation FD Disclosure
7:00am
8-K
EX-99.3
8qbjvz7
21 Dec 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
th3afwdr
7 Nov 23
Clene Reports Third Quarter 2023 Financial Results and Operating Highlights
8:02am
8-K
EX-1.1
pwic9o fr
16 Jun 23
Clene Announces Launch of Proposed Public Offering
5:06pm
424B3
8tjmqkj 6wa2kq0
10 Nov 21
Prospectus supplement
4:02pm
424B3
r7e6zb
10 Nov 21
Prospectus supplement
4:01pm
424B3
f8tup
2 Aug 21
Prospectus supplement
5:03pm
424B3
mx5pbznehgpf
21 Apr 21
Prospectus supplement
6:04am